|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings suggest that patient-specific responses to hormone therapies can be modeled and studied organotypically <i>in vitro</i> and add to evidence advocating obesity as a parameter to consider when identifying treatments for patients with ER-positive breast cancer.-Morgan, M. M., Arendt, L. M., Alarid, E. T., Beebe, D. J., Johnson, B. P. Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
|
31002529 |
2019 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thus, further delineation of the interaction of obesity, inflammation, and aromatase is required for the development of therapeutic treatment options.
|
30388923 |
2019 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
CYP19A1 increased with obesity in all depots (P < 0.001).
|
30562161 |
2019 |
|
Obesity
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In this propensity-matched cohort study, postmenopausal patients with breast cancer treated with aromatase inhibitors had increased risk of nonalcoholic fatty liver disease compared with healthy women after menopause, independent of obesity and diabetes mellitus.
|
30679317 |
2019 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
We hypothesized that aromatase inhibitors induce obesity and insulin resistance when used in treatment of breast cancer.
|
30920624 |
2019 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Obesity is associated with white adipose tissue (WAT) inflammation in the breast, elevated levels of the estrogen biosynthetic enzyme, aromatase, and systemic changes that predispose to breast cancer development.
|
29222346 |
2018 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
This review describes how obesity-related factors can affect the risk of hormone-dependent breast cancer, highlighting the different molecular mechanisms and metabolic pathways involved in aromatase regulation, estrogen production and breast malignancy in the context of obesity.
|
28919302 |
2018 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The BC risk related to obesity may be reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated concentrations of leptin; and decreases blood glucose levels and insulin resistance.
|
29415446 |
2018 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS.
|
28948418 |
2018 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
The current study aimed to determine whether stimulation of aromatase by obesity-associated adipokine leptin involves the regulation of the p53-HIF1α/PKM2 axis.
|
29104286 |
2018 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that treatment with DHA would reduce the expression of proinflammatory genes and aromatase, the rate-limiting enzyme for estrogen biosynthesis, in benign breast tissue of overweight/obese women.
|
29453232 |
2018 |
|
Obesity
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population-a preliminary study.
|
30232779 |
2018 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Here, we identified regulatory pathways in estrogen receptor-positive (ER-positive) tumors that were shared between patients with obesity and those with resistance to neoadjuvant aromatase inhibition.
|
30046001 |
2018 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Obesity is associated with breast white adipose tissue (WAT) inflammation, elevated levels of the estrogen biosynthetic enzyme, aromatase, and systemic changes that have been linked to the pathogenesis of breast cancer.
|
28270386 |
2017 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Increasing our knowledge on the role of aromatase in male obesity could help in proposing new approaches to treat infertile men.
|
28679145 |
2017 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MA20 and MA30 showed a preservation of their "metabolic memory" (increase of Leptin, ObR, VEGF, CYP19A1, and a decrease of Adiponectin expression in MA30 compared to MA20).
|
27886379 |
2017 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Breast adipose tissue inflammation in obesity is associated with an increase in the expression of the estrogen biosynthetic enzyme, aromatase, and is hypothesized to create a hormonal milieu conducive to tumor growth.
|
27423512 |
2017 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In particular, obesity-associated and tumor-derived factors, such as prostaglandin E2 (PGE2), have been shown to drive the expression of aromatase by stimulating the activity of the proximal promoter II (PII).
|
25634217 |
2015 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Evidence demonstrating a link between obesity and breast cancer has led to the investigation of metabolic pathways as novel regulators of estrogen production, including pathways that can be targeted to inhibit aromatase specifically within the breast.
|
26209254 |
2015 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
We conclude that obesity influences the response and resistance of breast cancer tumors to aromatase inhibitor treatment.
|
26113604 |
2015 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of stromal aromatase in obese females is regulated by DNA methylation.
|
24866503 |
2014 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In a mouse model of obesity, treatment with Zyflamend suppressed levels of phospho-Akt, NF-κB binding activity, proinflammatory mediators, and aromatase in the mammary gland.
|
23880231 |
2013 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Notably, this obesity-inflammation-aromatase axis provides a plausible explanation for increased rates of postmenopausal, hormone receptor-positive breast cancer associated with obesity and hence may offer targets for interventions to attenuate risk or improve prognosis.
|
23958744 |
2013 |
|
Obesity
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Inflammatory mediators regulate aromatase expression in the human breast as one mechanism whereby they increase the risk of breast cancer, especially in women who are obese.
|
24163427 |
2013 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
The obesity → inflammation → aromatase axis is likely to contribute to the increased risk of hormone receptor-positive breast cancer and the worse prognosis of obese patients with breast cancer.
|
22576212 |
2012 |